Prime Medicine Gets FDA Clearance to Start Human Testing of PM647 for Alpha-1 Antitrypsin Deficiency
First human data are due in 2027. This is not an approval; Beam remains ahead in patients.
First human data are due in 2027. This is not an approval; Beam remains ahead in patients.
Early lab results show Claude found a CRISPR-like repeat array tied to a reverse transcriptase. No proven editing tool yet.
Beam shares fell after updated BEAM-302 data showed durable AAT correction. Incremental results sparked classic biotech profit-taking.
Prime Medicine secures positive arbitration ruling against Beam Therapeutics: no damages owed for PM647 in AATD. IND/CTA filing planned for Q3 2026, first clinical data in 2027.
William Blair maintains Outperform rating on Beam Therapeutics after company announces FDA alignment for BEAM-302 and planned risto-cel application, citing clear regulatory pathway ahead.
Evercore ISI initiates coverage of Beam Therapeutics (BEAM) with an Outperform rating and $35 price target, citing promising early data for BEAM-302 in treating AATD and highlighting key data expected in Q1 2026.